检索结果-南通市图书馆

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

培哚普利治疗稳定性冠心病的耐受性研究

中华心血管病杂志 2007年第12期35卷 1130-1132页

作者： The investigators for the study on the Tolerability of Perindopril 培哚普利耐受性研究协作组

目的对稳定性冠心病患者,观察将培哚普利由4mg/d 调整至8mg/d 后的耐受性。方法开放性多中心研究。入组已经服用培哚普利4 mg/d 至少4周的稳定性冠心病患者,采用培哚普利8 mg/d 治疗2个月,观察增量后的安全性与耐受性。观察指标:不良事... 详细信息

目的对稳定性冠心病患者,观察将培哚普利由4mg/d 调整至8mg/d 后的耐受性。方法开放性多中心研究。入组已经服用培哚普利4 mg/d 至少4周的稳定性冠心病患者,采用培哚普利8 mg/d 治疗2个月,观察增量后的安全性与耐受性。观察指标:不良事件和严重不良事件、患者依从性,记录基线状态、第4周和第8周的血压、心率、血钾、钠、肌酐和尿素氮。结果共入选109例符合入选标准的稳定性冠心病患者。其中102例患者能够很好耐受培哚普利8 mg/d 治疗,总耐受率为93.6%。共计18例患者(占16.5%)发生不良事件,无严重不良事件发生。仅1例患者(占0.9%)因不良事件退出。培哚普利增量使基线血压未达标患者的血压由(149.4±7.6)/(84.1±11.0)mm Hg(1 mm Hg=0.133 kPa)下降至(128.8±14.2)/(79.5±8.9)mm Hg(均 P<0.01),而对基线血压达标患者的血压无影响。观察期间患者心率由(72.3±9.4)次/min 下降至(69.8±7.8)次/min(P<0.05),血电介质、肌酐和尿素氮水平无变化。结论中国稳定性冠心病患者对培哚普利8 mg/d 的治疗剂量耐受性良好。

关键词：冠状动脉疾病血管紧张素转换酶抑制药药物耐受性培哚普利稳定性冠心病

Association between coexisting intracranial artery and extracranial carotid artery atherosclerotic diseases and ipsilateral cerebral infarction: a Chinese Atherosclerosis Risk Evaluation (CARE- II) study

在线全文

学校读者我要写书评

暂无评论

Stroke & Vascular Neurology 2021年第4期6卷 595-602页

作者： Chunxiu Jiang Jing Zhang Jianbin Zhu Xianlong Wang Zhibo Wen Xihai Zhao Chun Yuan On behalf of CARE-II investigators Department of Radiology Zhujiang HospitalSouthern Medical UniversityGuangzhouChina Department of Radiology Foshan Women and Children Hospital Affiliated to Southern Medical UniversityFoshanChina Center for Biomedical Imaging Research Department of Biomedical EngineeringTsinghua UniversityBeijingChina Department of Radiology University of WashingtonSeattleWashingtonUSA 不详

Background To evaluate the association between coexisting intracranial and extracranial carotid artery atherosclerotic diseases and ipsilateral acute cerebral infarct(ACI)in symptomatic patients by using magnetic resonance(MR)vessel wall *** Symptomatic patients were recruited from a cross-sectional,multicentre study of Chinese Atherosclerosis Risk Evaluation(CARE-II).All patients underwent MR imaging for extracranial carotid arterial wall,intracranial artery and *** intracranial stenosis≥50%and extracranial carotid artery mean wall thickness(MWT)≥1 mm and plaque compositions at the same side were evaluated and the ipsilateral ACI was *** association between coexisting atherosclerotic diseases and ACI was evaluated using logistic *** 351 patients were *** with ipsilateral ACI had significantly greater prevalence of coexisting intracranial stenosis≥50%and carotid MWT≥1 mm(20.5%vs 4.9%,p<0.001),calcification(15.1%vs 4.4%,p=0.001)and lipid-rich necrotic core(LRNC)(19.2%vs 7.8%,p=0.002)compared with those *** intracranial artery stenosis≥50%and carotid MWT≥1 mm(OR 5.043,95%CI 2.378 to 10.694;p<0.001),calcification(OR 3.864,95%CI 1.723 to 8.664;p=0.001)and LRNC(OR 2.803,95%CI 1.455 to 5.401;p=0.002)were significantly associated with ipsilateral *** adjusting for confounding factors,the aforementioned associations remained statistically significant(intracranial stenosis≥50%coexisting with carotid MWT≥1 mm:OR 4.313,95%CI 1.937 to 9.601,p<0.001;calcification:OR 3.606,95%CI 1.513 to 8.593,p=0.004;LRNC:OR 2.358,95%CI 1.166 to 4.769,p=0.017).Conclusions Coexistence of intracranial artery severe stenosis and extracranial carotid artery large burden and intraplaque components of calcification and LRNC are independently associated with ipsilateral *** registration number https://***/.Unique identifier:NCT02017756.

关键词： intracranial carotid cerebral

Chinese Atherosclerosis Risk Evaluation(CARE II)study:a novel cross-sectional,multicentre study of the prevalence of high-risk atherosclerotic carotid plaque in Chinese patients with ischaemic cerebrovascular events-design and rationale

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Stroke & Vascular Neurology 2017年第1期2卷 15-20页

作者： Xihai Zhao Rui Li Daniel S Hippe Thomas S Hatsukami Chun Yuan CARE-II investigators Department of Biomedical Engineering Center for Biomedical Imaging ResearchTsinghua University School of MedicineBeijingChina Department of Radiology University of WashingtonSeattleWashingtonUSA Department of Surgery University of WashingtonSeattleWashingtonUSA 不详

Background:Carotid atherosclerotic plaque is identified as one of the main sources of ischaemic ***,the prevalence of carotid high-risk atherosclerotic plaque in Chinese patients with ischaemic cerebrovascular events has been inconsistently reported and needs to be investigated in a large ***:The primary objective of CARE II study was to determine the prevalence and characteristics of high-risk features of atherosclerotic plaques in the carotid arteries in Chinese patients with recent ischaemic stroke or transient ischaemia attack(TIA).The relationship between carotid plaque features and cerebral infarcts,the differences of carotid plaque patterns among different regions of China and the gender specific characteristics of carotid plaque will be also *** design:The CARE II study will enrol 1000 patients with recent ischaemic stroke or TIA and carotid plaque from 13 hospitals and medical centres across *** this cross-sectional,non-randomised,observational,multicentre study,all patients will undergo carotid artery MRI of bilateral carotid arteries and routine brain MRI with standardised *** MRI will be interpreted at core reading centres to evaluate the characteristics of morphology and compositions of carotid ***:This is a cross-sectional,multicentre study to investigate the prevalence and characteristics of high-risk atherosclerotic carotid plaque in Chinese patients with stroke and TIA by using high-resolution MRI of vessel *** trial is sufficiently powered to demonstrate the prevalence of carotid high-risk plaque and to explore regional differences in Chinese patients who suffered stroke.

关键词： prevalence carotid patients

Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Translational Neurodegeneration 2020年第1期9卷 96-104页

作者： Heinz Reichmann Andrew Lees José-Francisco Rocha Diogo Magalhaes Patrício Soares-da-Silva the OPTIPARK investigators Department of Neurology University of DresdenDresdenGermany University College London Reta Lila Weston InstituteLondonUK Global Parkinson’s Disease Department BIAL–Portela&CA S.ACoronadoPortugal Research and Development Department BIAL–Portela&CA S.Ada Siderurgia Nacional4745-457 S Mamede do CoronadoPortugal Department of Pharmacology and Therapeutics Faculty of MedicineUniversity PortoPortoPortugal MedInUP Center for Drug Discovery and Innovative MedicinesUniversity PortoPortoPortugal 不详

Background:The efficacy and safety of opicapone,a once-daily catechol-O-methyltransferase inhibitor,have been established in two large randomized,placebo-controlled,multinational pivotal ***,clinical evidence from routine practice is needed to complement the data from the pivotal ***:OPTIPARK(NCT02847442)was a prospective,open-label,single-arm trial conducted in Germany and the UK under clinical practice *** with Parkinson’s disease and motor fluctuations were treated with opicapone 50 mg for 3(Germany)or 6(UK)months in addition to their current levodopa and other antiparkinsonian *** primary endpoint was the Clinician’s Global Impression of Change(CGI-C)after 3 *** assessments included Patient Global Impressions of Change(PGI-C),the Unified Parkinson’s Disease Rating Scale(UPDRS),Parkinson’s Disease Questionnaire(PDQ-8),and the Non-Motor Symptoms Scale(NMSS).Safety assessments included evaluation of treatment-emergent adverse events(TEAEs)and serious adverse events(SAEs).Results:Of the 506 patients enrolled,495(97.8%)took at least one dose of *** these,393(79.4%)patients completed 3 months of ***,71.3 and 76.9%of patients experienced any improvement on CGI-C and PGI-C after 3 months,respectively(full analysis set).At 6 months,for UK subgroup only(n=95),85.3%of patients were judged by investigators as improved since commencing *** scores at 3 months showed statistically significant improvements in activities of daily living during OFF(mean±SD change from baseline:?3.0±4.6,p<0.0001)and motor scores during ON(?4.6±8.1,p<0.0001).The mean±SD improvements of?3.4±12.8 points for PDQ-8 and-6.8±19.7 points for NMSS were statistically significant versus baseline(both p<0.0001).Most of TEAEs(94.8%of events)were of mild or moderate *** considered to be at least possibly related to opicapone were reported for 45.1%of patients,with dyskinesia(11.5%)and dry mouth(6.5%)being

关键词： Levodopa Motor fluctuations Open-label Opicapone Parkinson’s disease

Association between stress hyperglycemia ratio and in-hospital outcomes:findings from the improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome(CCC-ACS)Project

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Geriatric Cardiology 2024年第6期21卷 658-668页

作者： Wen-Jie WANG Ke-Xin WANG Jia-Long NIU Yi-Xuan LIU Hai-Long GE Hua SHEN On behalf of CCC-ACS investigators Department of Cardiology Beijing Anzhen HospitalCapital Medical UniversityBeijingChina

BACKGROUND Stress hyperglycemia ratio(SHR)could provide accurate information on the acute status of *** relationship between SHR and acute coronary syndrome(ACS)prognosis remains *** study was conducted to identity the association between SHR and in-hospital outcomes in patients with *** A total of 12,010 patients were eventually enrolled in the *** relationship between SHR and in-hospital major adverse cardiovascular events(MACEs)was then modeled by restricted cubic spline(RCS)curves,and all patients were divided into three groups according to the *** multivariate logistic regression analysis was used to determine the associations between the SHR and in-hospital outcomes,described as odds ratios(ORs)and 95%confidence intervals(CIs).Subgroup analyses were also performed on different *** The median age of this cohort was 63(54,71)years old,and 8942(74.5%)were *** 1 was defined as SHR1(n=5763).Compared with Group 2,Group 1(OR=1.891,95%CI:1.028-3.479,P<0.001)and Group 3(OR=1.868,95%CI:1.434-2.434,P<0.001)had higher risks of suffering from in-hospital *** was associated with higher risks of in-hospital MACEs in the subgroups of DM[OR=2.282,95%CI:1.477-3.524).CONCLUSIONS Both low and high SHR levels were independently associated with in-hospital *** males with DM,hypertension,and decreased renal function had much higher risks of suffering from SHR-correlated MACEs.

关键词： acute cardiovascular finding

Cilostazol and isosorbide mononitrate for the prevention of progression of cerebral small vessel disease:baseline data and statistical analysis plan for the Lacunar Intervention Trial-2(LACI-2)(ISRCTN14911850)

在线全文

学校读者我要写书评

暂无评论

Stroke & Vascular Neurology 2023年第2期8卷 134-143页

作者： Philip M Bath Iris Mhlanga Lisa J Woodhouse Fergus Doubal Katherine Oatey Alan A Montgomery Joanna M Wardlaw LACI-Trial investigators Stroke Trials Unit University of NottinghamNottinghamUK Centre for Clinical Brain Sciences UK Dementia Research Institute CentreUniversity of EdinburghEdinburghUK Edinburgh Clinical Trials Unit University of EdinburghEdinburghUK Nottingham Clinical Trials Unit University of NottinghamNottinghamUK

Background Cerebral small vessel disease(SVD)causes lacunar strokes(25%of all ischaemic strokes),physical frailty and cognitive impairment and vascular and mixed *** is no specific treatment to prevent progression of *** The LACunar Intervention Trial-2 is an investigator-initiated prospective randomised open-label blinded-endpoint phase II feasibility study assessing cilostazol and isosorbide mononitrate for preventing SVD *** aimed to recruit 400 patients with clinically evident lacunar ischaemic stroke and randomised to cilostazol,isosorbide mononitrate,both or neither,in addition to guideline secondary ischaemic stroke prevention,in a partial factorial *** primary outcome is feasibility of recruitment and adherence to medication;key secondary outcomes include:drug tolerability;recurrent vascular events,cognition and function at 1 year after randomisation;and safety(bleeding,falls,death).Data are number(%)and median(IQR).Results The trial commenced on 5 February 2018 and ceased recruitment on 31 May 2021 with 363 patients randomised,with the following baseline characteristics:average age 64(56.0,72.0)years,female 112(30.9%),stroke onset to randomisation 79.0(27.0,244.0)days,hypertension 267(73.6%),median blood pressures 143.0(130.0,157.0)/83.0(75.0,90.0)mm Hg,current smokers 67(18.5%),educationally achieved end of school examinations(A-level)or higher 118(32.5%),modified Rankin scale 1.0(0.0,1.0),National Institutes Health stroke scale 1.0(1.4),Montreal Cognitive Assessment 26.0(23.0,28.0)and total SVD score on brain imaging 1.0(0.0,2.0).This publication summarises the baseline data and presents the statistical analysis *** The trial is currently in follow-up which will complete on 31 May 2022 with results expected in October *** registration number ISRCTN14911850.

关键词： nitrate initiated prevention

Development and validation of a score predicting mortality for older patients with mitral regurgitation

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Geriatric Cardiology 2023年第8期20卷 577-585页

作者： De-Jing FENG Yun-Qing YE Zhe LI Bin ZHANG Qing-Rong LIU Wei-Wei WANG Zhen-Yan ZHAO Zheng ZHOU Qing-Hao ZHAO Zi-Kai YU Hai-Tong ZHANG Zhen-Ya DUAN Bin-Cheng WANG Jun-Xing LV Shuai GUO Run-Lin GAO Hai-Yan XU Yong-Jian WU on behalf of the China-DVD and China-VHD study investigators Department of Cardiology Fuwai HospitalNational Center for Cardiovascular DiseaseChinese Academy of Medical Science and Peking Union Medical CollegeBeijingChina

OBJECTIVE To develop and validate a user-friendly risk score for older mitral regurgitation(MR)patients,referred to as the Elder-MR *** The China Senile Valvular Heart Disease(China-DVD)Cohort study functioned as the development cohort,while the China Valvular Heart Disease(China-VHD)study was employed for external *** included patients aged 60 years and above receiving medical treatment for moderate or severe MR(2274 patients in the development cohort and 1929 patients in the validation cohort).Candidate predictors were chosen using Cox’s proportional hazards model and stepwise selection with Akaike’s information *** Eight predictors were identified:age≥75 years,body mass index<20 kg/m^(2),NYHA class Ⅲ/Ⅳ,secondary MR,anemia,estimated glomerular filtration rate<60 mL/min per 1.73 m^(2),albumin<35 g/L,and left ventricular ejection fraction<60%.The model displayed satisfactory performance in predicting one-year mortality in both the development cohort(C-statistic=0.73,95%CI:0.69-0.77,Brier score=0.06)and the validation cohort(C-statistic=0.73,95%CI:0.68-0.78,Brier score=0.06).The Elder-MR score ranges from 0 to 15 *** a one-year follow-up,each point increase in the Elder-MR score represents a 1.27-fold risk of death(HR=1.27,95%CI:1.21-1.34,P<0.001)in the development cohort and a 1.24-fold risk of death(HR=1.24,95%CI:1.17-1.30,P<0.001)in the validation *** to EuroSCORE II,the Elder-MR score demonstrated superior predictive accuracy for one-year mortality in the validation cohort(C-statistic=0.71 vs.0.70,net reclassification improvement=0.320,P<0.01;integrated discrimination improvement=0.029,P<0.01).CONCLUSIONS The Elder-MR score may serve as an effective risk stratification tool to assist clinical decision-making in older MR patients.

关键词： patients mitral score

急性高血糖对ST段抬高性心肌梗死院内预后的影响

在线全文

学校读者我要写书评

暂无评论

中华内科杂志 2007年第10期46卷 820-823页

作者： Registry of acute treatment in myocardial infarction investigators. 心肌梗死紧急医学救治系统研究协作组

目的探讨急性高血糖对 ST 段抬高性心肌梗死(STEMI)患者院内预后的影响。方法连续入选356例北京地区17家三级和二级医院所有在24h 内入院且符合 STEMI 诊断标准的患者。以人院血糖水平>11mmol/L 判定为高血糖,分为高血糖组和血糖正常组... 详细信息

目的探讨急性高血糖对 ST 段抬高性心肌梗死(STEMI)患者院内预后的影响。方法连续入选356例北京地区17家三级和二级医院所有在24h 内入院且符合 STEMI 诊断标准的患者。以人院血糖水平>11mmol/L 判定为高血糖,分为高血糖组和血糖正常组,观察两组患者院内死亡和心血管病事件的发生情况。院内心血管事件定义为院内再发心肌梗死、新发生的心力衰竭、严重心律失常及卒中。结果 356例 STEMI 患者中,存在急性高血糖患者共81例(22.8%)。其院内病死率较无急性高血糖患者显著增加(13.6%比5.1%,P=0.009),院内心血管事件发生率亦显著增多(32.1%比20.4%,P=0.027)。logistic 回归分析示,入院急性高血糖(OR 1.615,95%CI 1.116～2.338,P=0.011)为 STEMI 患者院内不良预后的独立危险因素。结论 STEMI 急性高血糖患者院内死亡及发生院内心血管事件的危险性显著高于入院血糖正常者。入院高血糖为 STEMI 患者院内不良预后的独立危险因素。

关键词：高血糖症心肌梗塞预后

Thirty-day outcomes of in-hospital multi-vessel versus culpritonly revascularization strategy for ST-segment elevation myocardial infarction with multivessel coronary disease

在线全文

学校读者我要写书评

暂无评论

Journal of Geriatric Cardiology 2023年第7期20卷 485-494页

作者： Yu-Xi LI Bei-Ning WANG Fang-Fang FAN Yan ZHANG Jie JIANG Jian-Ping LI Ya-Ling HAN Yong Huo CCC investigators Department of Cardiology Peking University First HospitalBeijingChina Cardiovascular Research Institute and Department of Cardiology General Hospital of Northern Theater CommandShenyangLiaoningChina 不详

BACKGROUND Many studies have demonstrated the benefit of complete multivessel revascularization versus culprit-only intervention in patients of ST-segment elevation myocardial infarction(STEMI)and multivessel coronary artery ***,only a few single-center retrospective studies were performed on small Chinese *** study aims to demonstrate the advantage of multivessel percutaneous intervention(PCI)strategy on 30-day in-hospital outcomes to patients with STEMI and multivessel disease in larger Chinese *** From the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome(CCC-ACS)project,5935 patients with STEMI and multivessel disease undergoing PCI and hospitalized for fewer than 30 days were *** 5:1 propensity score matching,3577 patients with culprit-only PCI and 877 with in-hospital multivessel PCI were *** primary outcome was major adverse cardiovascular and cerebrovascular event(MACCE),defined as a composite of myocardial infarction,all-cause death,stent thrombosis,heart failure,and *** Multivariable logistic regression analysis revealed that in-hospital multivessel PCI was associated with lower risk of 30-day MACCE(adjusted OR=0.75,95%CI:0.57-0.98,P=0.032)than culprit-only PCI and conferred no increased risk of allcause death,myocardial infarction,stent thrombosis,stroke,or *** analysis showed that MACCE reduction was observed more often from patients with trans-femoral access(OR=0.34,95%CI:0.15-0.74)than with trans-radial access(OR=0.87,95%CI:0.66-1.16,P for interaction=0.017).CONCLUSIONS The in-hospital multivessel PCI strategy was associated with a lower risk of 30-day MACCE than culprit-only PCI in patients with STEMI and multivessel coronary artery disease.

关键词： infarction coronary myocardial